OUR IMPACT

 

Since 1976, the Samuel Waxman Cancer Research Foundation (SWCRF) has been recognized as a visionary pioneer in fundraising for cancer research. Every year, scientists from National Cancer Institute-designated research centers vie to be accepted into our exclusive network of investigators, the Institute Without Walls, undergoing a rigorous peer review by our distinguished Scientific Advisory Board. Once approved, grantees benefit from a collaborative environment of mutual information exchange and support that enhances the pace of their work.

Working across diverse cancer categories, our collaborators hail from the leading research institutes in the world, including Dana-Farber Cancer Institute, Weill Cornell Medical Center, Johns Hopkins University, MD Anderson Cancer Center, the Shanghai Institute of Hematology and many others.

The SWCRF is proud that many of our scientists’ innovative theories have been successfully applied to a wide range of cancer gene programming initiatives over the years.

Click here to view a timeline of scientific milestones from our funded researchers throughout our history.

 

HOW WE INVEST IN CANCERS

Over 40 years, we've raised approximately $90 million for more than 200 cancer researchers. In the past 10 years alone, our investment in a range of cancer categories has been more than $23 million, broken down as follows:

 

 

OUR ACHIEVEMENTS THROUGH COLLABORATION

Our impact on science’s quest for a cancer cure includes the following benchmarks:

 

LIVER CANCER

We pioneered the use of the first successful liver cancer drug treatment through an international consortium led by Mount Sinai.

 

BREAST CANCER

We created a novel combination of two existing cancer therapies for the treatment of hormone-resistant breast cancer, producing a new clinical trial at several New York hospitals led by Mount Sinai.

 

LEUKEMIA 

We partnered with researchers from the Shanghai Institute of Hematology to develop the first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide which increased the disease’s five-year survival rate from 25% to 95%.

 

PEDIATRIC CANCER 

We brought together scientists from the Harvard Cancer Center and the Dana-Farber Cancer Institute to develop a targeted therapy for a rare childhood cancer, which is currently in clinical trials.

 

LUNG CANCER

We advanced the paradigm of treatment for lung cancer by adding targeted drugs to chemotherapy through a collaboration between Dartmouth and Mount Sinai.

 

Click here to meet the leading researchers collaborating within our scientific brain trust.